KraneShares Emerging Markets Healthcare Index ETF
KMED
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 280 Park Avenue, 32nd Floor New York NY United States of America 10017
- IPO Date
- Oct 18, 2018
- CIK
- 0001547576
- Similar Companies
- Business
- KraneShares Emerging Markets Healthcare Index ETF (KMED) is an exchange-traded fund that tracks the Solactive Emerging Markets Healthcare Index, providing investors with targeted exposure to healthcare companies operating in emerging markets. The ETF invests primarily in equities of small-cap, mid-cap, and large-cap issuers across sub-sectors including hospital management and healthcare administration services; pharmaceutical manufacturing; biotechnology; and medical equipment providers; with key holdings such as Rede D or Sao Luiz SA, International Holdings Co PJSC, Samsung BioLogics Co Ltd, Bangkok Dusit Medical Services PCL, Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A, Jiangsu Hengrui Pharmaceuticals Co Ltd Class A, Celltrion Inc, IHH Healthcare Bhd, Celltrion Healthcare Co Ltd, and Aier Eye Hospital Group Co Ltd Class A. KMED maintains a portfolio of approximately 96 holdings, with roughly 39% of assets concentrated in its top 10 positions, and operates with a net expense ratio of 0.80%. Launched on August 29, 2018, and managed by Krane Funds Advisors, LLC, with headquarters in the United States, KMED focuses on the healthcare segment within emerging markets, targeting companies benefiting from rising healthcare spending as a percentage of GDP in regions such as China, India, and others through government initiatives like China's Healthy China 2030 Plan and India's National Health Protection Mission. The fund's geographic footprint spans emerging market countries worldwide, offering low correlation to U.S. healthcare equities and access to innovators in pharmaceutical research and aging population-driven demand. As of mid-2025, assets under management stand at approximately $1.89 million, with a dividend yield of 0.21%. In recent developments, KraneShares has continued to emphasize its suite of healthcare-focused ETFs, including KMED as part of expansions in emerging markets and China health care indices, though no major acquisitions, funding rounds, or product launches specific to KMED have been reported in the last 1-2 years. The ETF has maintained stable operations amid broader market interest in China tech and healthcare sentiment boosted by AI advancements as of early 2025. Holdings and index tracking remain consistent, supporting its role in diversified emerging markets healthcare investment strategies.